Constraints to cattle production in a semiarid pastoral system in Kenya

Livestock keeping is the mainstay for the pastoral community while also providing social and cultural value. This study ranked main production constraints and cattle diseases that impacted livelihood and estimated herd prevalence, incidence rate, and impact of diseases on production parameters in a semiarid pastoral district of Narok in Kenya. Data collection employed participatory techniques including listing, pairwise ranking, disease incidence scoring, proportional piling, and disease impact matrix scoring and this was disaggregated by gender. Production constraints with high scores for impact on livelihood included scarcity of water (19 %), lack of extension services (15 %), presence of diseases (12 %), lack of market for cattle and their products (10 %), and recurrent cycle of drought (9 %). Diseases with high scores for impact on livelihood were East Coast fever (ECF) (22 %) and foot and mouth disease (FMD) (21 %). High estimated incidence rates were reported for FMD (67 %), trypanosomosis (28 %), and ECF (15 %), while contagious bovine pleuropneumonia (CBPP) had an incidence rate <1 %. Milk yield was affected by FMD, ECF, and trypanosomosis, while ECF was the cause of increased mortality. FMD, ECF, CBPP, and brucellosis caused increased abortion, while effect of gender and location of study was not significant. Despite CBPP being regarded as an important disease affecting cattle production in sub-Sahara Africa, its estimated incidence rate in herds was low. This study indicates what issues should be prioritized by livestock policy for pastoral areas.     

Prevalence of contagious bovine pleuropneumonia (CBPP) in northern Nigeria

An abattoir study on the prevalence of contagious bovine pleuropneumonia (CBPP) in five cattle-producing states of Nigeria from 1988 to 1997 was carried out. A total of 1,936,015 slaughtered cattle was examined for characteristic CBPP lung lesions. The overall lesion-based prevalence of CBPP was 0.29% (95% CI 0.24, 0.35). The prevalence varied significantly (P<0.05) by state but not across the years. A total of 279 CBPP outbreaks occurred and overall vaccination coverage was only 9.7%, both varied over the years and across the states. The reasons for inadequate vaccination coverage for CBPP as well as the need for re-establishment of a national CBPP control programme are suggested.     

Seroprevalence of contagious bovine pleuropneumonia at export quarantine centers in and around Adama,Ethiopia

A cross sectional study was undertaken from October 2010 to March 2011 to determine the seroprevalence of contagious bovine pleuropneumonia (CBPP) and its related risk factors in export quarantine centers. A total of 3,111 cattle sera were collected from different export quarantine farms located in and around Adama, namely, Bekero, Jogo, Kedir, and Dera farms, and tested for the presence of Mycoplasma mycoides subsp. mycoides small colonies antibody using competitive enzyme-linked immunosorbant assay. Of the total 3,111 cattle sera examined, 124 (4 %) were found positive for CBPP. Among the potential predisposing factors assessed, origin, transportation condition, confinement level, and stay time of the animals in quarantine center were not found significantly (P?>?0.05) associated with the occurrence of the disease. Whereas age was found significantly (P?<?0.05) associated with the occurrence of the disease in which a high seroprevalence was recorded in aged (9.5 %) animals than young (3 %). Generally, this study showed that CBPP is a threat for Ethiopian livestock export market and a well established disease in Borana and Bale areas, where the animals originated.     

VACCINATION WITH BABESIA ARGENTINA IN 5 BEEF HERDS IN SOUTH-EASTERN QUEENSLAND

Observations on the use of a vaccine containing Babesia argentina in 5 partly susceptible beef herds in south-eastern Queensland were made on 1,029 female breeding cattle over a period of 4 years. Groups averaging about 20 heifers were given 0, 1, 2 or 3 vaccinations. Incidence derived from groups experiencing clinical attacks were 17.9% for unvaccinated cattle and 1.2% for vaccinates. Increasing the number of vaccinations did not appear to increase protection. The one clinical manifestation of infection with B. bigemina was associated with a concurrent reaction to vaccination with Anaplasma centrale. There were no cases of haemolytic anaemia in new-born calves. No severe reactions followed primary vaccination, but 2 revaccinated animals became sick.     

A heterogeneous population model for contagious bovine pleuropneumonia transmission and control in pastoral communities of East Africa

Pastoral cattle live in highly structured communities characterized by complex contact patterns. The present paper describes a spatially heterogeneous model for the transmission of contagious bovine pleuropneumonia (CBPP) developed specifically for pastoral communities of East Africa. The model is validated against serological data on the prevalence of CBPP infection in several communities of southern Sudan and against livestock owner information on community structure, livestock contact and cattle exchange. The model is used to assess the impact of alternative control strategies including mass and elective vaccination programmes, potential treatment regimes and the combination of vaccination and treatment in a single unified strategy. The results indicate that the eradication of CBPP using mass vaccination with currently available vaccines is unlikely to succeed. On the other hand, elective control programmes based on herd level vaccination, treatment of clinical cases or a combination of both vaccination and treatment enabled individual livestock owners to capture a large benefit in terms of reduced animal-level prevalence and mortality experience. The most promising intervention scenario was a programme which combined the vaccination of healthy animals with treatment of clinical cases.     

A two year BTV-8 vaccination follow up: molecular diagnostics and assessment of humoral and cellular immune reactions

The compulsory vaccination campaign against Bluetongue virus serotype eight (BTV-8) in Germany was exercised in the state of Bavaria using three commercial monovalent inactivated vaccines given provisional marketing authorisation for emergency use. In eleven Bavarian farms representing a cross sectional area of the state the immune reactions of sheep and cattle were followed over a two year period (2008-2009) using cELISA, a serum neutralisation test (SNT) and interferon gamma (IFN-γ) ELISPOT. For molecular diagnostics of BTV genome presence two recommended real time quantitative RT-PCR protocols were applied. The recommended vaccination scheme led to low or even undetectable antibody titers (ELISA) in serum samples of both cattle and sheep. A fourfold increase of the vaccine dose in cattle, however, induced higher ELISA titers and virus neutralising antibodies. Accordingly, repeated vaccination in sheep caused an increase in ELISA-antibody titers. BTV-8 neutralising antibodies occurred in most animals only after multiple vaccinations in the second year of the campaign. The secretion of interferon gamma (IFN-γ) in ELISPOT after in vitro re-stimulation of PBMC of BTV-8 vaccinated animals with BTV was evaluated in the field for the first time. Sera of BTV-8 infected or vaccinated animals neutralising BTV-8 could also neutralise an Italian BTV serotype 1 cell culture adapted strain and PBMC of such animals secreted IFN-γ when stimulated with BTV-1.     

Endurance of immunity against foot-and-mouth disease in cattle after three consecutive annual vaccinations

Protection against foot-and-mouth disease (FMD) and ability to transmit FMD virus to susceptible contact animals were studied in cattle vaccinated three times in annual field campaigns with the Dutch trivalent vaccine. Eighty vaccinated cattle and 16 susceptible controls were intranasally exposed to an aerosol containing a homologous FMD challenge virus (O1 BFS, A10 Holland or C1 Detmold) or a heterologous virus (A5 Modena or C1 Modena). The day after exposure, vaccinated cattle were stabled individually with an FMD-susceptible contact. All cattle challenged with an homologous virus strain at one year (20 head), at two years (10 head) and at three years (30 head) after the last vaccination were protected against the development of clinical signs of disease; one, zero and five cattle of these groups, respectively, transmitted virus to their contacts. In each group, approximately two out of three exposed cattle had virus-positive oropharyngeal fluid samples and seroconverted. The amount of virus recovered from probang samples increased with the time since the last vaccination. Mean antibody titres of cattle that had not been vaccinated for three consecutive years did not change significantly over the last two-year period. All 10 cattle challenged with the vaccine strain-related C1 Modena virus were protected against clinical disease, whereas three out of 10 challenged with the heterologous A5 Modena strain virus one year after the last vaccination contracted FMD and transmitted the virus. Five others (four in the C1 group and one in the A5 group) spread the virus to their contacts.(ABSTRACT TRUNCATED AT 250 WORDS)     

Danofloxacin (Advocin) reduces the spread of contagious bovine pleuropneumonia to healthy in-contact cattle

Contagious bovine pleuropneumonia (CBPP), caused by Mycoplasma mycoides subsp. mycoides SC (MmmSC), is one of the most important diseases of cattle in Sub-Saharan Africa. The live T1/44 vaccine is normally used for its control but produces only transient protection and gives rise to adverse reactions. The present study evaluated the efficacy of danofloxacin (2.5% Advocintrade mark, Pfizer Ltd.) for the treatment of naturally infected cattle and in the prevention of CBPP transmission to in-contact cattle. Adult cattle, taken from a natural outbreak, were placed into two groups of 10 animals and kept on a research farm in paddocks 50m apart. One group was treated with 2.5mg/kg danofloxacin on days 0, 1 and 2; the other group were saline treated. On day 2, 10 CBPP-free, seronegative cattle were placed in contact with each of the two groups. All cattle were monitored for 3.5 months. No differences were seen in clinical improvement of the CBPP-affected cattle treated with danofloxacin compared with the untreated CBPP-affected cattle with approximately half of each group being withdrawn because of CBPP or showing CBPP lesions at post mortem examination. Clinical scores of the two groups were also similar. However cattle kept in contact with the danofloxacin-treated CBPP-affected animals showed significantly fewer lesions, less mortality and fewer animals were seropositive (P<0.02) and had reduced clinical scores (P<0.001) compared to cattle kept in contact with untreated CBPP-affected cattle. MmmSC was also isolated from fewer contact controls kept with the treated group. These findings could have important implications for the control of CBPP in Africa.     

Characterization of the long-term immune response to vaccination against Mycobacterium avium subsp. paratuberculosis in Danish dairy cows

Vaccination of cattle against Mycobacterium avium subsp. paratuberculosis (MAP) provides partial protection by delayed shedding of MAP and reduced numbers of clinically affected animals. The duration of vaccine induced immune response is not known. The primary objective of this study was therefore to characterize the long-term effect of whole-cell based vaccination against MAP on the immune response. A secondary objective was to evaluate whether immunodiagnosis of MAP and Mycobacterium bovis infections is affected by MAP vaccination. Two studies were performed: (1) A retrospective longitudinal study including 895 vaccinated and 2526 non-vaccinated dairy cows in 9 Danish dairy herds aiming at characterizing the long-term antibody-response to vaccination; and (2) a cross-sectional study of responses in the IFN-γ assay carried out in 140 vaccinated animals in two herds to evaluate the effect of vaccination on the cell-mediated immune response and to evaluate a possible interference with the diagnosis of M. bovis infections. The results showed that 37% of samples from vaccinated animals and 5% of samples from non-vaccinated animals, respectively, were test positive in the milk antibody ELISA. The prevalence of antibody responses of the vaccinated animals was relatively constant from 2 to 6 years of age, but decreased in older animals. Among the 140 vaccinated animals 88% tested positive with the IFN-γ test to johnin PPD and 50% responded to PPDb with IFN-γ production above a similar cut-off. Although Denmark is free of M. bovis, two of the vaccinated animals responded with higher IFN-γ levels when cultured with PPDb compared to PPDa. In conclusion, immunization with whole-cell MAP vaccines elicits both humoral and cell-mediated immune reactions, which may interfere with surveillance and diagnosis of both MAP and M. bovis infections using currently available tests.     

Intranasal vaccination against upper respiratory tract disease (U.R.D.) in the cat—II. Results of field studies under enzootic conditions in The Netherlands with a combined vaccine containing live attenuated calici- and herpesvirus

A live vaccine containing attenuated calici- and herpesviruses was tested in field studies in the Netherlands.This vaccine is administered intranasally. Cats may show local transient reactions in the week following vaccination. The experiments were conducted in three types of infected premises: boarding catteries, homes for stray cats and breeding colonies. In the boarding catteries the vaccine was instilled intranasally at least one week before admission. If this was impossible—like it is in homes for stray cats—the animals were vaccinated at the day of admission and then quarantined for at least 24 hr.In the four boarding catteries 290 cats were vaccinated. Local reations were observed in 25 animals (less than 9%). Five cats (less than 2%) showed clinical symptoms of the disease in spite of vaccination. However these cases were all in the same cattery which also housed stray cats.In three homes for stray cats 257 animals were vaccinated. The percentage of local reactions was much higher (49%) due to suppressed infections and secondary bacterial invaders. Clinical disease was seen in 13 cats (5%). However eight of these cats were in one cattery where some of the requirements of the experiment—c.q. quarantine—could not be met.Prevention of the disease in infected breeding colonies was difficult to achieve because infected parent animals are known to shed virulent virus during rehousing and parturition.The following vaccination program was very successful: parent animals are vaccinated intranasally prior to mating and the pregnant queens again on the day of parturition. The kittens are then vaccinated intranasally at an age of 8–10 days old. With this program the percentage of healthy kittens that could be sold was as high as 98%. This compares to 66% in a previous vaccination program where the queens were given an intramuscular vaccine and the kittens received either several intramuscular vaccinations or one intranasal vaccination on the age of six days.The CH vaccine is available on the Dutch market for one year. The results obtained by veterinary practitioners confirm the good results obtained in the field studies.     

Analyses of baseline surveillance data on contagious bovine pleuropneumonia in the southern Sudan

In the first survey for contagious bovine pleuropneumonia (CBPP) in the southern region of the Sudan (Bahr el Ghazal Province), 8.1% of Dinka-owned, and 9.2% of Fellata-owned, cattle, and 48 and 20% of their respective herds were serologically positive for CBPP. Dinka cattle between 3 months and 3 years of age had significantly higher test reaction rates than those younger or older. There was a positive association between reaction rates and herd size. A similar association was found between crude mortality rates and herd size, though virtually none of the variability among herds in crude mortality was accounted for by presence of CBPP infection. Overall, the study indicated a highly endemic situation for CBPP infection with rare overt disease under conditions of little prior intervention. Under such conditions, it is suggested that a “surveillance and selective actions” rather than a “mass actions” approach might be the most suitable, with vaccination limited by surveillance to those areas at highest risk of outbreaks of clinically important CBPP, namely areas of low herd immunity or those where actual outbreaks of clinical disease have already occurred. Such an approach to CBPP could serve as a “model” for establishing a system of improved disease intelligence overall in the southern Sudan.     

The importance of allergic skin test with Johnin,antibody ELISA,cultural fecal test as well as vaccination for the sanitation of three chronically paratuberculosis-infected dairy herds in Rhineland-Palatinate

Three chronically paratuberculosis infected herds were tested for six years twice a year (intradermal Johnin test, antibody ELISA (IDEXX Corp.), microbial culture) according to a sanitary program. Culling of shedding animals and vaccination of calves with NEOPARASEC (Merial Corp.) were part of the program. In course of experiment, 1015 samples of 228 non vaccinated cows and 1502 samples of 293 vaccinated cattle have been tested. 3.8% of the vaccinated animals proved positive in microbial culture. Nearly all vaccinated calves developed granulomas sized from hazelnut to loaf at the injection site. Positive reactions in intradermal test as well as in antibody ELISA were found in very young calves. 24.3%, 33.7%, 25.9%, respectively of the non vaccinated animals were identified as shedders of M. avium subsp. paratuberculosis (MAP) by microbial culture. In the first and in the second herd most shedders of MAP were found in the first herd examination (66.7%, 42.9%, respectively), whereas in the third herd they were detected in the fifth examination (31.0%). At the beginning, 17.9% of non vaccinated animals proved positive in intradermal test, 14.4% in antibody ELISA. Afterwards, the number of positive test results decreased but increased again towards the end of the experiment. 48.5% of the 66 shedders showed positive reactions in intradermal test, 57.6% in antibody ELISA, 77.3% in at least one of these both tests. Antibodies in ELISA were found in rising frequency from two years before the time of shedding. 50.0% of the shedders reacted positive in ELISA at the time of shedding. In selected shedders first positive results were found at the age of about two years. Unfortunately, only incomplete hygienic measures were realized by the farmers. Under field conditions the realisation of attending sanitary programs is difficult. MAP is spread mainly by buying of animals, therefore a certification program for paratuberculosis free herds is urgently necessary as well as an improvement of diagnostic methods.     

Humoral response to West Nile virus vaccination in alpacas and llamas

OBJECTIVE: To determine humoral responses to an equine West Nile virus (WNV) vaccine in healthy alpacas and llamas and compare responses in alpacas and llamas with responses in horses. DESIGN: Clinical trial. ANIMALS: 28 alpacas, 56 llamas, and 16 horses. PROCEDURE: Horses received 2 vaccinations at 4-week intervals, and alpacas and llamas received 3 vaccinations at 3-week intervals. Fifty-five llamas received a fourth vaccination 3 weeks after the third. Blood samples were collected immediately prior to each vaccination, 3 weeks after the last vaccination for alpacas and llamas, and 4 weeks after the last vaccination for horses and tested for virus-neutralizing antibodies. Samples from 29 randomly selected vaccinated llamas were used. RESULTS: None of the animals developed any local or systemic adverse reactions. Four of 28 (14%) alpacas, 4 of 29 (14%) llamas, and 7 of 16 (44%) horses were seropositive 3 (llamas and alpacas) or 4 (horses) weeks after administration of the first vaccination; 27 of 28 (96%) alpacas, 26 of 29 (90%) llamas, and 15 of 16 (94%) horses were seropositive after administration of the second vaccination; and all 28 alpacas and 28 of 29 (97%) llamas were seropositive 3 weeks after administration of the third vaccination. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that vaccination with the equine WNV vaccine is safe in alpacas and llamas. Administration of 3 vaccinations generally resulted in virus-neutralizing antibody titers similar to those observed following 2 vaccinations in horses; however, because it is not known what antibody titer would be protective against clinical WNV disease in alpacas or llamas, we cannot conclude that the vaccine was efficacious.     

Economic evaluation of the production impact of bovine schistosomiasis and vaccination in the Sudan

This study was done to evaluate the estimated economic consequences of the recent discovery that an irradiated Schistosoma bovis vaccine was effective in reducing mortality and intensity of infection in cattle after field exposure to S. bovis in the White Nile province. The benefits and costs were hypothesized to occur over a 5-year period starting after the vaccine had been further developed to optimal commercial usefulness.

The potential benefits of vaccination are from the avoidance of mortality and growth delay losses caused by S. bovis infection and were based on an owner survey conducted in 1981. These benefits were discounted from the time of their potential marketing opportunity to the first year of a vaccination program at 15% per annum and were valued on a basis of 1982 prices for live cattle exported to Egypt and Saudi Arabia. Variations in benefits stem from degree of infection probability, mortality and morbidity estimates and percent of animals vaccinated. Since clinical schistosomiasis (“gorag” — sunken-eyed appearance) and associated production losses occur almost exclusively in 6- to 30-month-old cattle, and there is evidence for long-term immunity, vaccinations would be given to cattle in this age-specific group or younger once in their lifetime. The principal variation in vaccination program costs, also valued at 1982 prices, is from vaccine production costs; $0.50 or $4.00 per dose. A vaccine efficacy of 70%, observed in a previously reported field trial, was used in these calculations.

Present value benefit—cost (b–c) ratios were estimated for the central, western and southern areas for high- and low-level effects of S. bovis impact on production and the vaccination program, cost and effectiveness. In an area (central provinces) of high infection probability (90%), high percentage of animals vaccinated (90%), high mortality (7.1%), and low vaccine production costs, the b–c ratio was 12.7. In contrast, a b–c ratio of 0.7 was estimated for an area (southern provinces) assuming low infection probability (50%), low percent of animals vaccinated (50%), lower mortality (3.55%) and high vaccine production costs. Potential returns from increased future milk and calf production and from faster herd build-up with younger females were not included in these benefit calculations. These results indicate that under most conditions further development of the vaccine and cost-effective vaccine production techniques would yield very favorable returns from improved livestock production efficiency in the Sudan. Export prices were assumed to not vary significantly with increased supply of export-quality cattle resulting from the estimated production losses avoided by vaccination against schistosomiasis.     

Immune responses of Asian elephants (Elephas maximus) to commercial tetanus toxoid vaccine

Although captive elephants are commonly vaccinated annually against tetanus using commercially available tetanus toxoid vaccines marketed for use in horses and livestock, no data exists to prove that tetanus toxoid vaccination produces measurable antibody titers in elephants. An ELISA test was created to measure antibody responses to tetanus toxoid vaccinations in 22 Asian elephants ranging in age from 24 to 56 years (mean age 39 years) over a 7-month period. All animals had been previously vaccinated with tetanus toxoid vaccine, with the last booster administered 4 years before the start of the study. The great majority of elephants had titers prior to booster vaccination, and following revaccination all elephants demonstrated anamnestic increases in titers, indicating that this species does respond to tetanus vaccination. Surprisingly older animals mounted a significantly higher response to revaccination than did younger animals.     

Transmission of foot-and-mouth disease by vaccinated cattle following natural challenge

Cattle vaccinated with a conventional monovalent type O1 foot-and-mouth disease (FMD) vaccine were challenged between four and 21 days after vaccination by short-term exposure to homologous airborne virus produced by pigs. Transmission was then assessed by housing susceptible cattle with the vaccinated animals and testing and observing all the animals for signs of infection and clinical disease. All 18 cattle vaccinated three weeks before challenge resisted clinical disease and although four contracted subclinical infection, there was no transmission to susceptible cattle in contact. One of the two groups of cattle vaccinated two weeks previously transmitted subclinical infection, but not disease, to susceptible animals housed with them from day 0 after challenge. Subclinical infection was manifested by a transient viraemia which was not followed by a detectable circulating antibody response. Shorter periods (seven or four days) from vaccination to challenge resulted in transmission of disease from clinically normal vaccinated to in-contact animals in one of two experiments. The severe challenge presented by the diseased in-contact animals than overwhelmed the immunity of the vaccinated animals. The results indicate that during emergency vaccination programmes it is advisable to vaccinate all FMD-susceptible animals within the vaccination zone and that at the outer boundary of the zone vaccinated animals should be kept separated from unvaccinated animals for at least three weeks.     

Efficacy of two vaccine formulations against contagious bovine pleuropneumonia (CBPP) in Kenyan indigenous cattle

A live, attenuated vaccine is currently the only viable option to control of CBPP in Africa. It has been suggested that simple modifications to current vaccines and protocols might improve efficacy in the field. In this report we compared the current vaccine formulation with a buffered preparation that maintains Mycoplasma viability at ambient temperature for a longer time. Groups of animals were vaccinated with the two formulations and compared with non vaccinated groups. Half of the animals in each group were challenged 3 months post vaccination, the other half after 16 months. Protection levels were measured using the pathology index, calculated from post mortem scores of lesions from animals killed during the course of clinical disease. In the challenge at 3 months post vaccination, the protection levels were 52% and 77% for the modified and current vaccine preparations, respectively. At 16 months post vaccination, the protection levels were 56% and 62% for the modified and current vaccine preparations, respectively. These findings indicate that there are no differences in protection levels between the two vaccines. Because of its longer half life after reconstitution, the modified vaccine might be preferred in field situations where the reconstituted vaccine is likely not to be administered immediately.     

Persistence of the protective immunity to Schistosoma japonicum in Chinese yellow cattle induced by recombinant 26kDa glutathione-S-transferase (reSjc26GST)

To observe the long lasting effect of the recombinant Sj26GST sub-unit vaccine against Schistosoma japonicum in cattle, animals aged from 5 to 12 months were vaccinated with reSjc26GST, and were challenged by natural infection 6 months or 12 months after vaccination. Worm burdens per cattle and egg burden in tissue (per gram) of cattle with or without vaccination were compared. The results showed that anti-reSjc26GST antibodies were produced in vaccinated cattle. Following natural infection, the vaccinated and the control non-vaccinated cattle were all found to be infected with S. japonicum. A 30% reduction in worm number was observed in the vaccinated cattle when compared with the control cattle. The anti-fecundity effect was characterized by an average of 60% decrease in eggs deposited in the liver of vaccinated cattle; such a decrease is obviously very significant. In addition to the anti-fecundity effect induced in the vaccinated cattle, the number of miracidum hatched per 50 g faeces and the number of eggs released in intestinal tissues per gram were reduced or decreased. Results suggested that the immune responses induced by reSjc26GST in cattle were similar to that in buffaloes and in pigs. In addition, our result demonstrated that the lasting effect of immunity to S. japonicum induced in cattle after vaccination with reSjc 26 GST could persist at least 12 months.     

Improvement of trivalent leptospira vaccine by removal of anaphylactic agents

The anaphylactic reactions in cattle following leptospira vaccination mostly booster dose in different parts of Iran have been reported. The serum proteins as allergic substances are components of liquid phase of the vaccine. Therefore, the vaccine was modified by washing the whole cultures by centrifugations. The modified vaccine was safe in laboratory animals and cattle as well as under field conditions. Microagglutination test revealed a similar pattern of antibody response to the three Leptospira interrogans serovars (Canicola, Grippotyphosa, and Sejro hardjo) in all vaccinated cattle groups while was higher than the response of control animals. The results of the present investigation revealed that we can minimize postvaccination shock in vaccinated cattle populations with removing the shock proteins.     

Serological response of cattle to simultaneous vaccinations against foot-and-mouth disease and haemorrhagic septicaemia

In Malaysia, where vaccination campaigns against foot-and-mouth disease and haemorrhagic septicaemia are routinely carried out, it was desirable to determine whether it was safe and efficacious to administer both vaccines simultaneously. A trial group of 104 cattle was divided into three groups; group 1 animals received both vaccines simultaneously, group 2 animals received only foot-and-mouth disease vaccine and group 3 animals received only haemorrhagic septicaemia vaccine. The serological response to vaccinations was monitored at 0, 21 and 35 days by the virus neutralisation test for foot-and-mouth disease and the mouse-protection and indirect haemagglutination tests for haemorrhagic septicaemia. The simultaneous administration of the two inactivated vaccines produced no adverse effects and the serological response did not differ from the response to either vaccine given separately, thus indicating that cattle may be safely and effectively vaccinated simultaneously in this way.